All relevant data are within the paper and its Supporting Information file.

Background {#sec005}
==========

Antiretroviral therapy (ART) substantially reduces the incidence of acquired immunodeficiency syndrome (AIDS) and mortality, with increased CD4 cell count significantly and independently associated with improved prognosis \[[@pone.0156099.ref001]--[@pone.0156099.ref004]\]. Some patients do not achieve CD4 cell count reconstitution with ART, despite achieving suppression of HIV viral load in the blood \[[@pone.0156099.ref005]\]. This paradoxical response is referred to by various terms in the literature including discordant immune response (DIR), poor or suboptimal immune reconstitution, incomplete immune recovery or restoration and immunological non-response. Here, we use the term discordant immune response as it was the term most frequently used by the included studies \[[@pone.0156099.ref006]--[@pone.0156099.ref010]\]. There is currently no agreed case definition for DIR.

Over 13 million people worldwide are on ART, with a further 22 million eligible \[[@pone.0156099.ref011]\]. Understanding limitations to its success will be critical in improving individual responses to treatment and regimen durability. The 2013 World Health Organization (WHO) consolidated guidelines on treatment of HIV now favour use of HIV viral load monitoring for routine identification of ART treatment failure \[[@pone.0156099.ref012]\], but CD4 cell counts for patients established on ART remain an important clinical and prognostic tool and are essential for identifying DIR \[[@pone.0156099.ref013], [@pone.0156099.ref014]\].

Much research has focused on CD4 reconstitution on ART, but the mechanisms promoting DIR are not well understood. Damage to CD4 T cells begins prior to ART initiation due to direct effects of the HIV virus on thymic tissue and depletion of progenitor cells\[[@pone.0156099.ref015]\]. Thymic output may be disproportionally affected in patients who start ART at lower CD4 counts leading to under-reconstitution of naïve CD4 T cells\[[@pone.0156099.ref016], [@pone.0156099.ref017]\]. Lymph node fibrosis is also major feature and correlates with duration of HIV infection prior to ART initiation \[[@pone.0156099.ref018], [@pone.0156099.ref019]\]. Untreated HIV infection leads to a significant activation of the immune system \[[@pone.0156099.ref020]\], resulting in a cycle of systemic inflammation, persistent T cell activation, exhaustion and death \[[@pone.0156099.ref021]--[@pone.0156099.ref023]\]. The extent of immune activation at the time of ART initiation is associated with the development of DIR \[[@pone.0156099.ref004], [@pone.0156099.ref024]\] and predicts mortality on ART \[[@pone.0156099.ref025]\]. HIV induced T cell dysfunction and inflammation are closely related to serious non-AIDS events \[[@pone.0156099.ref020], [@pone.0156099.ref026]\]. Persistent immune activation is often detected despite virologically suppressive ART \[[@pone.0156099.ref027]\] and can be driven by microbial translocation\[[@pone.0156099.ref028]\], low level persistent HIV viral replication\[[@pone.0156099.ref029]\], and latent co-infections such as CMV \[[@pone.0156099.ref030], [@pone.0156099.ref031]\] and tuberculosis \[[@pone.0156099.ref032], [@pone.0156099.ref033]\]. Innate immune cells including monocytes, macrophages and NK cells also perpetuate immune activation, but this axis is more specifically driven microbial translocation, LPS antigenaemia and circulating soluble CD14 and does not necessarily correlate with T cell activation \[[@pone.0156099.ref034]--[@pone.0156099.ref037]\].

Non-systematic reviews have previously been carried out into aetiologies, prevalence and potential management of DIR \[[@pone.0156099.ref038]--[@pone.0156099.ref044]\]. However, the literature is heterogeneous and in order to better understand the burden of DIR, we sought to systematically characterise the risk of mortality, AIDS and serious non-AIDS events associated with DIR across the published literature.

Methods {#sec006}
=======

The study protocol was registered with the Centre for Review Dissemination, University of York (registration number CRD42014010821). The systematic review has been reported in accordance with the PRISMA guidelines \[[@pone.0156099.ref045]\] (See [S1 Checklist](#pone.0156099.s001){ref-type="supplementary-material"}).

Eligibility criteria {#sec007}
--------------------

### Participants {#sec008}

Participants were aged 16 years or older and no restrictions were placed on language or geographical region.

Participants with DIR were defined as patients who had been taking ART for at least 6 months and who were virologically suppressed, but had a suboptimal CD4 count according to study definitions. Studies defined a suboptimal CD4 count in terms of either a failure to achieve a pre-specified rise in CD4 count or a pre-specified absolute CD4 value at a specific time point following ART initiation. Virological suppression was defined as at least one single HIV viral load measurement of below 1000 copies/ml after at least 6 months of ART. Studies that did not report on the virological status of the cohort were not included.

### Outcomes {#sec009}

Studies were included if they estimated the risk of mortality, AIDS or serious non-AIDS events associated with DIR. Studies were included if death was verified by clinician review, tracing or verbal autopsy. AIDS was defined as any illness that met criteria for a WHO stage 4 condition \[[@pone.0156099.ref046]\]. Serious non-AIDS events were defined as illnesses not included in the WHO Clinical Staging System, and which were non-communicable. These include non-communicable cardiovascular, liver, renal and bone diseases as well as non-AIDS related malignancies. Studies reporting AIDS and serious non-AIDS events were deemed to meet our inclusion criteria if the events had been verified at least by clinician review of participant records.

### Study design {#sec010}

Studies were eligible for inclusion if they were cohort studies or randomised controlled trials (RCTs). We excluded editorials and comments, case reports and case series, qualitative studies, mathematical modelling studies, and economic analyses.

Information sources and search methods {#sec011}
--------------------------------------

We searched the following databases: Cochrane Central Register of Controlled Trials (CENTRAL, in the Cochrane Library issue 1, 2016); MEDLINE (PubMed; 1966 to 31^st^ December 2015); EMBASE (OVID; 1980 to 31^st^ Decemeber 2015). [Table 1](#pone.0156099.t001){ref-type="table"} shows the search strategy used in Medline (PubMed); this was modified for the other electronic databases.

10.1371/journal.pone.0156099.t001

###### Search strategy.

![](pone.0156099.t001){#pone.0156099.t001g}

  Search                                                
  ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  [\#16]{.ul}                                           Search **(\#5) AND \#15**
  [\#15]{.ul}                                           Search **(((((((((\#6) OR \#7) OR \#8) OR \#9) OR \#10) OR \#11) OR \#12) OR \#13) OR \#14) OR \#15** Field: **Title/Abstract**
  [\#14]{.ul}                                           Search **incomplete CD4\* response** Field: **Title/Abstract**
  [\#13](http://www.ncbi.nlm.nih.gov/pubmed/advanced)   Search **discordant\*** Field:Title/Abstract
  [\#12]{.ul}                                           Search **immunovirological discordance\*** Field: **Title/Abstract**
  [\#11](http://www.ncbi.nlm.nih.gov/pubmed/advanced)   Search **low CD4\*** Field: **Title/Abstract**
  [\#10]{.ul}                                           Search **insufficient CD4\*** Field: **Title/Abstract**
  [\#9](http://www.ncbi.nlm.nih.gov/pubmed/advanced)    Search **suboptimal CD4\*** Field: **Title/Abstract**
  [\#8]{.ul}                                            Search **low responder\*** Field: **Title/Abstract**
  [\#7]{.ul}                                            Search **suboptimal immune response\*\[Title/Abstract\]**
  [\#6](http://www.ncbi.nlm.nih.gov/pubmed/advanced)    Search **suboptimal immune reconstitution** \[**Title/Abstract\]**
  [\#5](http://www.ncbi.nlm.nih.gov/pubmed/advanced)    Search **(\#1) AND \#4**
  [\#4](http://www.ncbi.nlm.nih.gov/pubmed/advanced)    Search **(\#2) OR \#3**
  [\#3](http://www.ncbi.nlm.nih.gov/pubmed/advanced)    Search **(antiretroviral\[Title/Abstract\]) OR ART\[Title/Abstract\]**
  [\#2]{.ul}                                            Search **antiretroviral therapy \[Title/Abstract\]**
  [\#1](http://www.ncbi.nlm.nih.gov/pubmed/advanced)    Search **\"HIV Infections\"\[Mesh\]**

Study Selection and Data Collection {#sec012}
-----------------------------------

Titles of studies identified from the database search were independently reviewed by two authors (CK and KG) and were excluded if the study was unrelated to the review subject. Remaining studies underwent independent abstract review and then full text review by the same two reviewers. Pre-piloted data extraction forms were independently applied to all studies that underwent full text review. Where disagreement occurred, a consensus was reached by discussion or a third reviewer was consulted (PM). Where outcome data were not reported, the lead study author was contacted.

Risk of bias {#sec013}
------------

Risk of bias assessment was based on the Cochrane Tool for Assessing Risk of Bias in Cohort Studies \[[@pone.0156099.ref047]\]. The Cochrane Tool for Assessing Risk of Bias in Randomised Control Trials was not used because no RCTs targeting DIR were identified that met the inclusion criteria. Potential sources of bias were assessed in three domains: 'study design'; 'comparability'; and 'assessment of outcomes'.

The study design domain assessed whether participants were selected to be representative of adults on ART, and if there were clear selection criteria for those with and without DIR. Studies with more stringent selection criteria based on, for example, frequency of CD4 and viral load monitoring or attendance at routine clinics prior to enrolment, were deemed to be at a high risk of bias because they might exclude populations at higher risk of DIR and therefore were not representative of the entire population of patients with DIR. The comparability domain assessed if patients with and without DIR were managed according to the same standardised protocol and if outcomes were reported after appropriate adjustment for potential confounding variables. For the assessment of outcomes domain, outcomes had to be measured using clinician review, case note review, verbal autopsy or autopsy. Studies that did not report at least one of these methods were deemed high risk of bias for this category. The minimum acceptable follow-up period was one year as this is the highest risk period for adverse clinical outcomes post ART initiation \[[@pone.0156099.ref048]\].

An overall risk of bias assessment was made for each individual domain. A domain would be classified as high risk of bias if any one question within it failed the specified criteria. Where insufficient information had been reported in a study to make a judgement on the risk of bias, that question was recorded as unclear. 'Unclear' and 'high risk' categories were then combined for the purposes of analysis \[[@pone.0156099.ref049]\].

Summary measures and synthesis of results {#sec014}
-----------------------------------------

For each study, the proportion of participants with and without DIR who died, and/or experienced an AIDS-related, or serious non-AIDS-related event were estimated. Risk ratios and 95% confidence were extracted from the manuscript or calculated. A meta-analysis with pooled effect estimates were planned but could not be carried out due to considerable variation in both DIR definition and length of follow-up.

Results {#sec015}
=======

Study selection {#sec016}
---------------

2782 study titles were identified by the search. Twenty studies met inclusion criteria for full-text review ([Fig 1](#pone.0156099.g001){ref-type="fig"}). The two most common reasons for exclusion were that the study did not report a clinical outcome (36%) and the cohort was not virally suppressed (23%). Authors from the study by Young *et al* were contacted to clarify if participants had been on ART for at least 6 months but the data were no longer available and so the study was excluded.

![Flow of paper selection from those identified following literature search through to inclusion.](pone.0156099.g001){#pone.0156099.g001}

Study characteristics {#sec017}
---------------------

Twenty studies were included \[[@pone.0156099.ref004], [@pone.0156099.ref006]--[@pone.0156099.ref009], [@pone.0156099.ref050]--[@pone.0156099.ref064]\], all of which were cohort studies. For three studies, the cohort was established *de novo* to investigate the effects of DIR on clinical outcomes \[[@pone.0156099.ref004], [@pone.0156099.ref051], [@pone.0156099.ref058], [@pone.0156099.ref064]\]. One study analysed DIR and outcomes in the control arm of an RCT assessing ART regimes for individuals initiating ART \[[@pone.0156099.ref050]\]. The remaining 14 studies conducted secondary analysis of existing datasets comprising of national or international cohorts of HIV infected patients who had data collected prospectively and systematically during routine clinical care \[[@pone.0156099.ref006]--[@pone.0156099.ref009], [@pone.0156099.ref052]--[@pone.0156099.ref057], [@pone.0156099.ref059]--[@pone.0156099.ref063]\].

Seventeen studies recruited participants from HIV care clinics. Five studies included participants from resource-limited countries \[[@pone.0156099.ref004], [@pone.0156099.ref009], [@pone.0156099.ref058], [@pone.0156099.ref063], [@pone.0156099.ref064]\]: three from countries with a generalised HIV epidemic (Uganda, South Africa) \[[@pone.0156099.ref004], [@pone.0156099.ref058], [@pone.0156099.ref064]\]; one from Senegal \[[@pone.0156099.ref063]\]; and one from an international collaboration of both low-, and middle-income countries \[[@pone.0156099.ref009]\]. Participants were ART-naïve in 16 studies \[[@pone.0156099.ref004], [@pone.0156099.ref006]--[@pone.0156099.ref009], [@pone.0156099.ref050], [@pone.0156099.ref051], [@pone.0156099.ref053], [@pone.0156099.ref055]--[@pone.0156099.ref060], [@pone.0156099.ref063], [@pone.0156099.ref064]\] whereas four studies included patients who were ART naïve and experienced \[[@pone.0156099.ref052], [@pone.0156099.ref054], [@pone.0156099.ref061], [@pone.0156099.ref062]\].

For included studies, the median proportion of male participants ranged from 31%-- 100% and median age ranged from range 34 to 43 years ([Table 2](#pone.0156099.t002){ref-type="table"}). Median CD4 cell count at ART initiation was reported for 15 studies and ranged from 80--221 cells/mm^3^. Median HIV viral load at ART initiation was reported for 10 studies and ranged from 4.5 log~10~−5.1 log~10~ copies/ml. The threshold for defining virological suppression ranged from \<50 copies/ml to \<1000 copies per ml. Participant follow-up ranged from 1 to 7 years.

10.1371/journal.pone.0156099.t002

###### Description of 20 included studies.
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  -------------------------------------- ---------------------------------------------------------------- ------------------------- ---------------------------------- ---------------------------------------------------- ------------------------------------------------ -------------------------------------------------------------------------- ---------------- ------------------------------------------ ------------------------------------------ --------------------------------------------- -------------------------------------------------------
  **Study author**                       **Study design**                                                 **Year of publication**   **Median Duration of follow-up**   **Country**                                          **Setting**                                      **Relevant Outcomes examined**                                             **ART naïve?**   **%Male**                                  **Median age (years)**                     **Median CD4 (cells/uL) at ART initiation**   **Median HIV VL (log10 copies/mL) at ART initiation**
  BAKER \[[@pone.0156099.ref050]\]       Control arm of ART RCT                                           2008                      5 years                            USA                                                  Community, 80 sites                              Predictors and clinical outcomes of patients with DIR                      Yes              80                                         39                                         221                                           5.0
  BATISTA \[[@pone.0156099.ref063]\]     Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2015                      7 years                            Senegal                                              HIV care clinic                                  Frequency and risk factors for DIR, and incidence of OI and death          Yes              35                                         40                                         Not reported                                  Not reported
  DRONDA \[[@pone.0156099.ref051]\]      Prospective cohort study[^1^](#t002fn002){ref-type="table-fn"}   2002                      3 years                            Spain                                                HIV care clinic                                  Immunologic and clinical outcomes of patients with DIR                     Yes              74                                         36                                         196                                           5.0
  ENGSIG \[[@pone.0156099.ref052]\]      Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2010                      4.7 years                          Denmark                                              HIV care clinics, 8 sites                        Predictors and mortality of patients with DIR                              No               78                                         43[^5^](#t002fn006){ref-type="table-fn"}   Not reported                                  Not reported
  FALSTER \[[@pone.0156099.ref053]\]     Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2008                      5.4 years                          Australia                                            HIV care clinics, number of sites not reported   Prevalence of DIR, and and clinical outcomes                               Yes              93[^5^](#t002fn006){ref-type="table-fn"}   Not reported                               Not reported                                  Not reported
  GILSON \[[@pone.0156099.ref006]\]      Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2010                      3 years                            UK                                                   HIV care clinics, 10 sites                       Predictors and clinical outcomes                                           Yes              75                                         37                                         170                                           5
  **Study author**                       **Study design**                                                 **Year of publication**   **Median Duration of follow-up**   **Country**                                          **Setting**                                      **Relevant Outcomes examined**                                             **ART naïve?**   **%Male**                                  **Median age (years)**                     **Median CD4 (cells/uL) at ART initiation**   **Median HIV VL (log10 copies/mL) at ART initiation**
  GRABAR \[[@pone.0156099.ref054]\]      Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2000                      18 months                          France                                               HIV care clinics, 68 sites                       Clinical outcomes of patients with DIR                                     No               79                                         37                                         150                                           4.54
  GUTERRIEZ \[[@pone.0156099.ref055]\]   Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2008                      2.3 years                          Spain                                                HIV care clinics, 10 sites                       Predictors and clinical outcomes of patients with DIR                      Yes              75                                         37                                         160                                           5.0
  HUNT \[[@pone.0156099.ref004]\]        Prospective cohort study[^1^](#t002fn002){ref-type="table-fn"}   2011                      2 years                            Uganda                                               HIV care clinic                                  Mortality according to CD4 account[^3^](#t002fn004){ref-type="table-fn"}   Yes              30                                         34                                         135                                           5.1
  KAUFMANN \[[@pone.0156099.ref056]\]    Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2004                      5 years                            Switzerland                                          HIV care clinics, number of sites not reported   Predictors and clinical outcomes of patients with DIR                      Yes              74                                         38                                         180                                           4.9
  LOUTFY \[[@pone.0156099.ref057]\]      Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2010                      2.7 years                          Canada                                               HIV care clinics, 9 sites                        Clinical outcomes of patients with DIR                                     Yes              83                                         40                                         180                                           5.0
  MOORE \[[@pone.0156099.ref007]\]       Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2005                      3.7 years                          Canada                                               HIV care clinic                                  Predictors and mortality in patients with DIR                              Yes              77[^5^](#t002fn006){ref-type="table-fn"}   39                                         199                                           Not reported
  NAKANJAKO \[[@pone.0156099.ref058]\]   Prospective cohort study[^1^](#t002fn002){ref-type="table-fn"}   2008                      1.8 years                          Uganda                                               HIV care clinic                                  Prevalence of DIR and clinical outcomes                                    Yes              31                                         38                                         98                                            Not reported
  **Study author**                       **Study design**                                                 **Year of publication**   **Median Duration of follow-up**   **Country**                                          **Setting**                                      **Relevant Outcomes examined**                                             **ART naïve?**   **%Male**                                  **Median age (years)**                     **Median CD4 (cells/uL) at ART initiation**   **Median HIV VL (log10 copies/mL) at ART initiation**
  NICASTRI \[[@pone.0156099.ref061]\]    Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2005                      3.7 years                          Italy                                                Hospital, 63 sites                               Immunologic and clinical outcomes                                          No               72                                         35                                         185                                           4.78
  PACHECO \[[@pone.0156099.ref059]\]     Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2009                      6 years                            Spain                                                Hospital, 10 sites                               CD4 count recovery, predictors and mortality in patients with DIR          Yes              32[^5^](#t002fn006){ref-type="table-fn"}   Not reported                               Not reported                                  Not reported
  TAKUVA \[[@pone.0156099.ref064]\]      Prospective cohort study[^1^](#t002fn002){ref-type="table-fn"}   2014                      2 years                            South Africa                                         HIV care clinic, 1 site                          Mortality and AIDS associated with DIR                                     Yes              36                                         39                                         80                                            Not reported
  TAN \[[@pone.0156099.ref008]\]         Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2008                      3.2 year                           USA                                                  HIV care clinic                                  Clinical outcomes in patients with DIR                                     Yes              76                                         38                                         213                                           5.4
  TAIWO \[[@pone.0156099.ref062]\]       Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2009                      Not reported                       USA                                                  HIV care clinics, 4 sites                        Clinical outcomes in patients with DIR                                     No               100                                        42                                         Not reported                                  Not reported
  TUBOI \[[@pone.0156099.ref009]\]       Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2010                      1 year                             Multi-centre[^4^](#t002fn005){ref-type="table-fn"}   HIV care clinics, 31 centres                     Mortality in patients with DIR                                             Yes              39                                         34                                         100                                           Not reported
  ZOUFALY \[[@pone.0156099.ref010]\]     Established HIV cohort[^2^](#t002fn003){ref-type="table-fn"}     2010                      3.8 years                          Germany                                              HIV care clinics, 11 sitess                      Predictors and clinical outcomes in patients with DIR                      Yes              77                                         39                                         80                                            Not reported
  -------------------------------------- ---------------------------------------------------------------- ------------------------- ---------------------------------- ---------------------------------------------------- ------------------------------------------------ -------------------------------------------------------------------------- ---------------- ------------------------------------------ ------------------------------------------ --------------------------------------------- -------------------------------------------------------

ART = anti-retroviral therapy, cART = combination anti-retroviral therapy, DIR = discordant immune response, VL = Viral load, PI = Protease inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, DDI = didanosine, TDF = tenofovir, LMIC- = Low and middle income countries.

^1^ Patients are enrolled specifically for the aims of the current study.

^2^ Retrospective analysis of prospectively collected data.

^3^Analysis of clinical outcomes in DIR is a secondary analysis in this study.

^4^Includes countries from Africa, South America and Asia.

^5^Not reported for entire cohort therefore median value from optimal immune response group reported.

Risk of bias {#sec018}
------------

Two (10%) studies had a high risk of bias in study design; 6 (30%) in comparability; and 11 (55%) in assessment of outcomes ([Table 3](#pone.0156099.t003){ref-type="table"}).

10.1371/journal.pone.0156099.t003

###### Risk of bias assessment for 20 included studies.
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  Study                                  Study design   Comparability   Assessment of outcomes   Overall risk of bias                                                                       
  -------------------------------------- -------------- --------------- ------------------------ ---------------------- --------- ---------- --------- --------- --------- ----- ---------- ----------
  BAKER \[[@pone.0156099.ref050]\]       Yes            Yes             **Low**                  Yes                    Unclear   **High**   Yes       Yes       Unclear   Yes   **High**   **High**
  BATISTE \[[@pone.0156099.ref063]\]     Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       No        Yes   **High**   **High**
  DRONDA \[[@pone.0156099.ref051]\]      Yes            Yes             **Low**                  Yes                    No        **High**   Yes       Yes       Yes       Yes   **Low**    **High**
  ENGSIG \[[@pone.0156099.ref052]\]      No             Yes             **High**                 Yes                    No        **High**   Yes       Yes       Unclear   Yes   **High**   **High**
  FALSTER \[[@pone.0156099.ref053]\]     Yes            Yes             **Low**                  Yes                    No        **High**   Yes       Yes       Unclear   Yes   **High**   **High**
  GILSON \[[@pone.0156099.ref006]\]      Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Unclear   Yes   **High**   **High**
  GRABAR \[[@pone.0156099.ref054]\]      Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Unclear   Yes   **High**   **High**
  GUTERRIEZ \[[@pone.0156099.ref055]\]   Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Yes       Yes   **Low**    **Low**
  HUNT \[[@pone.0156099.ref004]\]        Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Yes       Yes   **Low**    **Low**
  KAUFMANN \[[@pone.0156099.ref056]\]    No             Yes             **High**                 Yes                    No        **High**   Unclear   Yes       No        Yes   **High**   **High**
  LOUTFY \[[@pone.0156099.ref057]\]      Yes            Yes             **Low**                  Yes                    Yes       **Low**    Unclear   Yes       No        Yes   **High**   **High**
  MOORE \[[@pone.0156099.ref007]\]       Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Yes       Yes   **Low**    **Low**
  NAKANJAKO \[[@pone.0156099.ref058]\]   Yes            Yes             **Low**                  Yes                    No        **High**   Yes       Yes       No        Yes   **High**   **High**
  NICASTRI \[[@pone.0156099.ref061]\]    Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Yes       Yes   **Low**    **Low**
  PACHECO \[[@pone.0156099.ref059]\]     Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       No        Yes   **High**   **High**
  TAKUVA \[[@pone.0156099.ref064]\]      Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Yes       Yes   **Low**    **Low**
  TAN \[[@pone.0156099.ref008]\]         Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Yes       Yes   **Low**    **Low**
  TAIWO \[[@pone.0156099.ref062]\]       Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Unclear   Unclear   Yes   **High**   **High**
  TUBOI \[[@pone.0156099.ref009]\]       Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Yes       Yes   **Low**    **Low**
  ZOUFALY \[[@pone.0156099.ref010]\]     Yes            Yes             **Low**                  Yes                    Yes       **Low**    Yes       Yes       Unclear   Yes   **High**   **High**

For the study design domain, Engsig *et al* required a viral load of \<50 copies /ml for more than three consecutive years before the start of the DIR observation period \[[@pone.0156099.ref052]\], and Kaufmann *et al* required a viral load of \<1000 copies/mL during the entire 5-year observation period \[[@pone.0156099.ref056]\]. The frequency of visits these criteria would require may have excluded patients at higher risk of DIR. All studies detailed clear selection criteria for participants with and without DIR.

For the comparability domain, participants with and without DIR were managed according to the same treatment protocols for all studies but 6 studies did not appropriately evaluate the effects of confounders on outcomes \[[@pone.0156099.ref050]--[@pone.0156099.ref053], [@pone.0156099.ref056], [@pone.0156099.ref058]\].

For the assessment of outcomes domain, two studies gave no information on how deaths \[[@pone.0156099.ref056], [@pone.0156099.ref057]\] or AIDS events \[[@pone.0156099.ref057]\] were ascertained. Eleven studies did not describe how missing data were handled \[[@pone.0156099.ref006], [@pone.0156099.ref050], [@pone.0156099.ref052], [@pone.0156099.ref053], [@pone.0156099.ref056]--[@pone.0156099.ref060], [@pone.0156099.ref062], [@pone.0156099.ref063]\].

Definition of DIR {#sec019}
-----------------

Definitions of DIR varied significantly and were classified into two categories: a failure to achieve a prespecified absolute CD4 count at a predefined time point; or a failure to achieve a prespecified rise in CD4 count from baseline at a predefined time point ([Table 4](#pone.0156099.t004){ref-type="table"}). Five studies explored several potential definitions of DIR \[[@pone.0156099.ref006], [@pone.0156099.ref010], [@pone.0156099.ref057], [@pone.0156099.ref058], [@pone.0156099.ref064]\].

10.1371/journal.pone.0156099.t004

###### Effect of DIR on rate of clinical outcomes, according to DIR definitions, for 20 studies reporting clinical outcomes.
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  Definition of discordant immune response                                                              First Author                           HIV viral load cut off         Number virologically suppressed   Number virologically suppressed with DIR   Effect of DIR on risk of Mortality   Effect of DIR on risk of AIDS   Effect of DIR on risk of AIDS or mortality                                                                               
  ----------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------ --------------------------------- ------------------------------------------ ------------------------------------ ------------------------------- -------------------------------------------- ----------- ----------- --------------------- -------------- -------------- ------------------------------
  Failure to achieve rise in CD4 count of \> = 50 cells/mm^3^ at 6 months after ART initiation          MOORE \[[@pone.0156099.ref007]\]       \<500 at 6 months              1084                              235                                        53 (22.6)                            61 (7.2)                        3.14 (2.24--4.40)                            NR          NR          NR                    NR             NR             NR
                                                                                                        TAN \[[@pone.0156099.ref008]\]         Undetected at 6 months         320                               35                                         4 (11.4)                             11 (3.9)                        2.96 (1.00--8.80)                            6 (17.1)    30 (10.5)   1.63 (0.73--3.54)     NR             NR             NR
                                                                                                        TUBOI \[[@pone.0156099.ref009]\]       \<500 at 6 months              6234                              1260                                       23 (4.5)                             51 (1.0)                        1.78 (1.09--2.90)                            NR          NR          NR                    NR             NR             NR
  Failure to achieve rise in CD4 count of \> = 50 cells/mm^3^ at 8 months after ART initiation          BAKER \[[@pone.0156099.ref050]\]       \<400 at 8 months              850                               149                                        7 (4.7)                              19 (2.7)                        1.73 (0.74--4.03)                            16 (10.7)   33 (4.7)    2.28 (1.29--4.02)     NR             NR             NR
  Failure to achieve rise in CD4 count of \> = 50 cells/mm^3^ at 12 months after ART initiation         GRABAR \[[@pone.0156099.ref054]\]      \<1000 at 6 months             1486                              387                                        NR                                   NR                              NR                                           NR          NR          NR                    37 (9.6)       51 (4.8)       1.99 (1.33--2.99)
                                                                                                        GUTERRIEZ \[[@pone.0156099.ref055]\]   \<500 throughout follow-up     650                               108                                        8 (7.4)                              10 (1.8)                        4.01 (1.62--9.94)                            3 (2.8)     15 (2.8)    1.00 (0.30 ---3.41)   NR             NR             NR
  Failure to achieve rise in CD4 count of \> = 100 cells/mm^3^ at 12 months after ART initiation        DRONDA \[[@pone.0156099.ref051]\]      \<50 quarterly for 2 years     288                               76                                         NR                                   NR                              NR                                           NR          NR          NR                    7 (9.2)        40 (18.9)      0.86 (0.41--1.80)
                                                                                                        NAKANJAKO \[[@pone.0156099.ref058]\]   \<400 quarterly for 2 years    339                               151                                        NR                                   NR                              NR                                           14 (9.3)    9 (4.8)     1.94 (0.86--4.35)     NR             NR             NR
  Failure to achieve rise in CD4 count of \> = 100 cells/mm^3^ at 12 months after ART                   NICASTRI \[[@pone.0156099.ref061]\]    \<500 at 12 months             1117                              336                                        NR                                   NR                              NR                                           NR          NR          NR                    Not reported   Not reported   Odds ratio 2.32 (1.36--3.95)
  Failure to achieve rise in CD4 count of \> = 100 cells/mm^3^ at 8 months after ART initiation         GILSON \[[@pone.0156099.ref006]\]      \<50 twice over one year       2584                              571                                        26 (4.6)                             24 (2.0)                        2.29 (1.33--3.97)                            15 (2.6)    33 (2.8)    0.96 (0.53--1.76)     NR             NR             NR
  Failure to achieve an absolute CD4 count of \> = 174cells/mm^3^ at 6 months after ART initiation^1^   HUNT \[[@pone.0156099.ref004]\]        \<1000 throughout follow-up    451                               107                                        3 (2.8)                              6 (1.7)                         1.00 (0.26--3.92)                            NR          NR          NR                    NR             NR             NR
  Failure to achieve an absolute CD4 count of \> = 350 cells/mm^3^ at 9 months after ART initiation     FALSTER \[[@pone.0156099.ref053]\]     \<400 twice over one year      292                               83                                         NR                                   NR                              NR                                           NR          NR          NR                    14 (3.5)       35 (2.2)       2.06 (0.89--4.79)
  Failure to achieve an absolute CD4 count of \> = 200 cells/mm^3^ at 12 months after ART               ZOUFALY \[[@pone.0156099.ref010]\]     \<50 throughout follow-up      1085                              248                                        NR                                   NR                              NR                                           18 (7.3)    11 (1.3)    2.70 (1.29--5.66)     NR             NR             NR
                                                                                                        LOUTFY \[[@pone.0156099.ref057]\]      \<50 throughout                2028                              404                                        NR                                   NR                              NR                                           NR          NR          NR                    14 (3.5)       35 (2.2)       1.61 (0.87--2.96)
  Failure to achieve an absolute CD4 count of \> = 250 cells/mm^3^ at 22 months after ART initiation    PACHECO \[[@pone.0156099.ref059]\]     \<1000 quarterly for 2 years   147                               40                                         5 (12.5)                             4 (3.7)                         3.23 (0.89--11.77)                           NR          NR          NR                    NR             NR             NR
  Failure to achieve an absolute CD4 count of \> = 200 cells/mm^3^ at 36 months after ART initiation    ENGSIG \[[@pone.0156099.ref052]\]      \<50 over 3 years              291                               55                                         11 (20)                              11 (4.7)                        4.29 (1.96--9.38)                            NR          NR          NR                    NR             NR             NR
  Failure to achieve an absolute CD4 count of \> = 500 cells/mm^3^ at 60 months after ART               KAUFMANN \[[@pone.0156099.ref056]\]    \<1000 over 5 years            293                               105                                        22 (21.0)                            18 (9.6)                        2.19 (1.23--3.89)                            NR          NR          NR                    NR             NR             NR

NR not reported. DIR discordant immune response IR concordant immune response. VL viral load.

Eleven studies defined DIR based on a failure to achieve a rise in CD4 from ART initiation \[[@pone.0156099.ref006]--[@pone.0156099.ref009], [@pone.0156099.ref050], [@pone.0156099.ref051], [@pone.0156099.ref054], [@pone.0156099.ref055], [@pone.0156099.ref058], [@pone.0156099.ref061], [@pone.0156099.ref063]\] and used CD4 count thresholds of a failure to achieve a rise of at least 50 cells/ mm^3^ at 6 months \[[@pone.0156099.ref007]--[@pone.0156099.ref009], [@pone.0156099.ref063]\]; at least 100 cells/ mm^3^ at 12 months \[[@pone.0156099.ref051], [@pone.0156099.ref058]\]; at least 50 cells/ mm^3^ at 12 months \[[@pone.0156099.ref054], [@pone.0156099.ref055]\]; at least 50 cells/ mm^3^ at 8 months \[[@pone.0156099.ref050]\]; and at least 100 cells/ mm^3^ at 8 months \[[@pone.0156099.ref006]\].

Nine studies defined DIR based on a failure to achieve an absolute CD4 count at a predefined time point \[[@pone.0156099.ref004], [@pone.0156099.ref010], [@pone.0156099.ref052], [@pone.0156099.ref053], [@pone.0156099.ref056], [@pone.0156099.ref057], [@pone.0156099.ref059], [@pone.0156099.ref062], [@pone.0156099.ref064]\] and used the following CD4 count thresholds: 200 cells/ mm^3^ at 6 months\[[@pone.0156099.ref064]\], 200 cells/ mm^3^ at 12 months \[[@pone.0156099.ref010], [@pone.0156099.ref057]\]; of 350 cells/ mm^3^ at 9 months \[[@pone.0156099.ref053]\]; of 250 cells/ mm^3^ at 22 months \[[@pone.0156099.ref059]\]; 200 cells/ mm^3^ at 36 months \[[@pone.0156099.ref052]\]; and 500cells/ mm^3^ at 60 months \[[@pone.0156099.ref056]\]. Hunt and colleagues described mortality according to tertiles of CD4 counts in patients with viral suppression rather than use a single definition for DIR \[[@pone.0156099.ref004]\] so we compared mortality in the highest tertile (\>177 cells/mm^3^) to the lowest tertile (\<95 cells/mm^3^), using the lowest tertile of CD4 counts as the 'DIR group'.

HIV VL cut offs used by studies to define virological suppression were as follows: 50 copies/ml (seven studies) \[[@pone.0156099.ref006], [@pone.0156099.ref010], [@pone.0156099.ref051], [@pone.0156099.ref052], [@pone.0156099.ref057], [@pone.0156099.ref062], [@pone.0156099.ref063]\]; 400 copies/ml (four studies) \[[@pone.0156099.ref050], [@pone.0156099.ref053], [@pone.0156099.ref058], [@pone.0156099.ref064]\]; 500 copies/ml (four studies) \[[@pone.0156099.ref007], [@pone.0156099.ref009], [@pone.0156099.ref055], [@pone.0156099.ref061]\]; and 1000 copies/ml (four studies) \[[@pone.0156099.ref004], [@pone.0156099.ref054], [@pone.0156099.ref056], [@pone.0156099.ref059]\]. One study only reported using an 'undetectable' VL \[[@pone.0156099.ref008]\]. The time period for the definition of virological suppression was as follows: a one off cut off point between 6 months to a year post ART (eight studies) \[[@pone.0156099.ref007]--[@pone.0156099.ref009], [@pone.0156099.ref050], [@pone.0156099.ref054], [@pone.0156099.ref061], [@pone.0156099.ref063], [@pone.0156099.ref064]\]; two measurements over one year (two studies) \[[@pone.0156099.ref006], [@pone.0156099.ref053]\]; quarterly measurements for 2 years (two studies) \[[@pone.0156099.ref051], [@pone.0156099.ref058], [@pone.0156099.ref059]\], and quarterly measurements throughout the period of follow-up (seven studies) \[[@pone.0156099.ref004], [@pone.0156099.ref010], [@pone.0156099.ref055]--[@pone.0156099.ref057], [@pone.0156099.ref062], [@pone.0156099.ref065]\].

Effect of DIR on risk of mortality {#sec020}
----------------------------------

The risk of mortality ranged between 3% to 23% for patients with DIR and 1% to 7% for patients without DIR, over a median follow-up time of 2 years and 3.7 years respectively. Ten studies estimated the effect of DIR on mortality \[[@pone.0156099.ref004], [@pone.0156099.ref006]--[@pone.0156099.ref009], [@pone.0156099.ref050], [@pone.0156099.ref052], [@pone.0156099.ref055], [@pone.0156099.ref056], [@pone.0156099.ref059]\] ([Table 4](#pone.0156099.t004){ref-type="table"}). Risk ratios ranged between 1.00 (95% CI 0.26--3.92) and 4.29 (95% CI 1.96--9.38). Six of nine studies showed a significantly higher risk of mortality in participants with DIR compared to participants without DIR \[[@pone.0156099.ref006]--[@pone.0156099.ref009], [@pone.0156099.ref055], [@pone.0156099.ref056]\] ([Fig 2A](#pone.0156099.g002){ref-type="fig"}). Two studies reported on the absolute risk of mortality in participants with DIR in resource-limited settings \[[@pone.0156099.ref004], [@pone.0156099.ref009]\], with Tuboi *et al* finding DIR to be significantly associated with an increased risk of death.

![**Forest plot showing risk of clinical outcomes for patients with DIR across those studies reporting each outcome: A) Mortality B) AIDS events C) Combined mortality and AIDS events**.](pone.0156099.g002){#pone.0156099.g002}

Ten studies reported the incidence of mortality in participants with DIR ([Table 5](#pone.0156099.t005){ref-type="table"}). Six found the incidence of mortality to be significantly higher in participants with DIR compared to participants without DIR \[[@pone.0156099.ref006]--[@pone.0156099.ref009], [@pone.0156099.ref055], [@pone.0156099.ref064]\]. Incidence rate ratios ranged from 1.78 (95% CI 1.09--2.90) to 4.01 (95% CI 1.62--9.94). One study from a sub-Saharan Africa setting (South Africa) reported rates of mortality and found an IRR of 1.78 (1.09--2.90). No differences in risk of mortality were found according to DIR defined as absolute or rise, CD4 count cut off or time period post ART initiation.

10.1371/journal.pone.0156099.t005

###### Effect of DIR on rate of clinical outcomes, according to DIR definitions, for 10 studies reporting incidence data.

![](pone.0156099.t005){#pone.0156099.t005g}

  Definition of discordant immune response *(time periods are length of time following ART initiation)*   First Author                         HIV viral load cut off         Number virologically suppressed   Number virologically suppressed with DIR   Effect of DIR on rate of Mortality   Effect of DIR on rate of AIDS   Effect of DIR on rate of AIDS or mortality                                                                      
  ------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------------ --------------------------------- ------------------------------------------ ------------------------------------ ------------------------------- -------------------------------------------- ---------- ---------- --------------------- ---------- ----------- --------------------
  Failure to achieve rise in CD4 count of \> = 50 cells/mm^3^ after 6 months                              BATISTA \[[@pone.0156099.ref063]\]   \<50 at 6 months               657                               102                                        NR                                   NR                              NR                                           NR         NR         NR                    47 (9.8)   202 (7.8)   1.21 (0.85--1.72)
                                                                                                          MOORE \[[@pone.0156099.ref007]\]     \<500 at 6 months              1084                              235                                        53 (5.7)                             61 (1.8)                        3.2 (3.9--12.7)                              NR         NR         NR                    NR         NR          NR
  Failure to achieve an absolute CD4 count of \> = 200 cells/mm^3^ after 6 months                         TAKUVA \[[@pone.0156099.ref064]\]    \<400 at 6 months              4129                              NR                                         NR                                   NR                              2 (1.44--2.79)                               NR         NR         1.67 (1.27--2.21)     NR         NR          NR
  Failure to achieve rise in CD4 count of \> = 100 cells/mm^3^ after 8 months                             GILSON \[[@pone.0156099.ref006]\]    \<50 twice over one year       2584                              571                                        26 (3.5)                             24 (0.5)                        7.00 (3.9--12.7)                             15 (2.0)   33 (0.7)   2.9 (1.4--5.4)        NR         NR          NR
  Failure to achieve rise in CD4 count of \> = 50 cells/mm^3^ after 12 months                             GRABAR \[[@pone.0156099.ref054]\]    \<1000 at 6 months             1486                              387                                        NR                                   NR                              NR                                           NR         NR         NR                    37 (6.6)   51 (1.8)    3.7 (2.3--5.7)
  Failure to achieve an absolute CD4 count of \> = 200 cells/mm^3^ after 12 months                        ZOUFALY \[[@pone.0156099.ref010]\]   \<50 throughout                1085                              248                                        18 (4.4)                             11 (1.6)                        2.8 (1.2--6.4)                               NR         NR         NR                    NR         NR          NR
                                                                                                          LOUTFY \[[@pone.0156099.ref057]\]    \<50 throughout                2028                              404                                        NR                                   NR                              NR                                           NR         NR         NR                    14 (1.1)   35 (0.8)    1.4 (0.7--2.6)
  Failure to achieve an absolute CD4 count of \> = 250 cells/mm^3^ after 22 months                        PACHECO \[[@pone.0156099.ref059]\]   \<1000 quarterly for 2 years   147                               40                                         5 (2.4)                              4 (0.7)                         3.2 (0.70--16.4)                             NR         NR         NR                    NR         NR          NR
  Failure to achieve an absolute CD4 count of \> = 200 cells/mm^3^ after 36 months                        ENGSIG \[[@pone.0156099.ref052]\]    \<50 over 3 years              291                               55                                         26 (3.5)                             24 (0.5)                        4.4 (1.7--11.3)                              NR         NR         NR                    NR         NR          NR
  Failure to achieve an absolute CD4 count of \> = 200 cells/mm^3^ after 6 months                         TAIWO \[[@pone.0156099.ref062]\]     \<50 biannually throughout     NR                                NR                                         NR                                   NR                              5.96 (0.40--87.8)                            NR         NR         HR 22.8 (1.89--275)   NR         NR          HR 10.7 (1.65--70)

NR not reported. DIR discordant immune response IR concordant immune response. VL viral load. py person years HR hazard ratio

Effect of DIR on risk of AIDS and serious non-AIDS events {#sec021}
---------------------------------------------------------

Six studies reported AIDS events \[[@pone.0156099.ref006], [@pone.0156099.ref008], [@pone.0156099.ref010], [@pone.0156099.ref050], [@pone.0156099.ref055], [@pone.0156099.ref058]\]. The risk ratio for associations between DIR and AIDS events ranged from 0.96 (95% CI 0.53--1.76) to 2.70 (95% CI 1.29--5.66) ([Fig 2B](#pone.0156099.g002){ref-type="fig"}). One of these reported AIDS events in a low resource setting (Uganda) with a risk ratio of 1.94 (0.86--4.35). Five studies reported combined AIDS events or mortality \[[@pone.0156099.ref051], [@pone.0156099.ref053], [@pone.0156099.ref054], [@pone.0156099.ref057], [@pone.0156099.ref061]\] and risk ratios ranged from 0.86 (95% CI 0.41--1.80) to 2.06 (95% CI 0.89--4.79) ([Fig 2C](#pone.0156099.g002){ref-type="fig"}). One study from a low resource setting (Senegal) reported an incidence rate ratio of 1.21 (0.85--1.72).

Four studies detailed AIDS events. The most commonly reported pathologies were oesophageal candidiasis, tuberculosis, AIDS related cancers, *pneumocystis jirovecii* and bacterial pneumonia \[[@pone.0156099.ref050], [@pone.0156099.ref055], [@pone.0156099.ref058], [@pone.0156099.ref060]\]. Only Baker *et al* included serious non-AIDS events \[[@pone.0156099.ref050]\], reporting events in eight of 143 patients (5.6%) with DIR compared to 31 of 671 patients (4.6%) without.

Discussion {#sec022}
==========

The main finding of this review was that we found definitions used to categorise DIR varied widely, with 14 different definitions used in the 20 included studies. This greatly limits the ability to draw conclusions about clinical burden in this patient cohort. This paper has synthesised existing data and suggested the definition for DIR to be a rise of less than 50 cells/uL at 6 months following ART initiation in those who have achieved virological suppression but with a CD4 count of less than 350 cells/uL. This provides a starting point for the development of consensus within the field. For the majority of included studies, mortality in patients with DIR was two to three times higher than in those with a satisfactory immune response. To our knowledge, this is the first review to systematically examine the fate of adults with DIR. Two further important gaps in the literature were identified: the large majority of current data reports on cohorts from high income countries; and only one study reported on the burden of serious non-AIDS events. Both the clinical burden of DIR in low income settings and the global burden of serious non-AIDS events remain unclear. It is not possible to draw comparisons between the risks associated with DIR in low resource to high resource settings with the current literature.

Although pooled meta-analysis was inhibited by heterogeneity in length of follow-up, mortality rates remain substantially and significantly elevated in patients with DIR in studies that reported rates adjusted for time. The relationship between DIR and AIDS is less clear and may be complicated by challenges in diagnosing or reporting AIDS conditions. Alternatively, other conditions such as serious non-AIDS events may be contributing to mortality and this warrants further investigation.

The scope of this review was also limited by heterogeneity in DIR definitions. In order to address this, we advocate the use of a standard definition. To define DIR based on a failure to achieve a rise in CD4 from baseline is more reflective of the amount of time spent at a lower CD4 count, which is an important predictor of poor outcomes \[[@pone.0156099.ref014]\]. In contrast, an absolute CD4 count at a given time point may only tell us about that point in time, when other factors such as co-existing infections may be affecting the CD4 count. The expected rate of CD4 reconstitution following ART initiation is 20 to 30 cells per month in the first 6 months and then 5 to 10 cells per month between 6 months and 24 months \[[@pone.0156099.ref066], [@pone.0156099.ref067]\]. Therefore, when choosing a time point to measure DIR, we believe that 6 months after ART initiation is logical.

Many studies included in this review based their definition of DIR on a failure to achieve a rise of 50 cells/uL at 6 months post ART initiation. Whilst this is a relatively strict CD4 cut off, these studies still reported a high proportion of virologically-suppressed patients with DIR. We would therefore recommend defining DIR as a rise of less than 50 cells/uL at 6 months following ART initiation in patients who have achieved virological suppression. This definition has the benefit of identifying a high risk group of patients early on in the course of their ART management to allow for increased benefit of any potential intervention. It is logical that this definition would only apply to those commencing ART with a CD4 \<350 cells/uL so as not to over diagnose DIR in a population starting with higher CD4 counts. The heterogeneity in definitions for DIR and outcome measures means that it is not currently possible to compare the utility of definitions to predict clinical outcomes. We recommend further studies to clinically validate a standardised definition.

This review should be interpreted in the light of several limitations. Firstly, the majority of studies were carried out using data collected from ongoing multicentre cohort studies, meaning cohorts are likely to be highly selected in terms of laboratory monitoring and attending follow-up visits. This limits the generalizability of the studies, and may mean that the risk of adverse clinical outcomes in individuals with DIR could be underestimated. Secondly, the HIV viral load limit defining virological suppression varied across studies. However, it remains unclear whether differences in viral load below 1000 copies/ml are biologically significant \[[@pone.0156099.ref068]\]. Lastly, individual studies did not distinguish between early mortality in patients starting ART with advanced immunosuppression and long term mortality due to poor immune reconstitution. This could be addressed in future studies.

There are currently no effective therapeutic options to reduce the excess mortality associated with DIR and further research is required. One approach under evaluation is to target underlying drivers of immune activation and inflammation. The addition of raltegravir to standard two class regimes at ART initiation has the aim of decreasing viral set point but as yet only two small studies have shown any effect on immune responses \[[@pone.0156099.ref069], [@pone.0156099.ref070]\]. Similarly a recent trial with valganciclovir to tackle ongoing CMV replication failed to show any improvement in CD4 count \[[@pone.0156099.ref071]\]. Although probiotics can improve the systemic pro-inflammatory profile, there is no evidence that this can improve CD4 counts \[[@pone.0156099.ref072]\]. To address generalised inflammation, anti-inflammatory agents such as statins and anti-rheumatic agents have been tested \[[@pone.0156099.ref073], [@pone.0156099.ref074]\]. Whilst statins reduced peripheral immune cell activation, there is no evidence that they can improve CD4 T cell count. Studies investigating the role of quinolones in reducing HIV related immune activation have shown only small decreases in inflammatory markers \[[@pone.0156099.ref075]\]. Immunomodulatoy agents such as IL-2 have shown limited success \[[@pone.0156099.ref076], [@pone.0156099.ref077]\] and current focus is being placed on IL-7 therapy \[[@pone.0156099.ref078], [@pone.0156099.ref079]\] with several ongoing trials in progress. Lastly, agents aimed at stimulating thymic output have also been tested in early studies \[[@pone.0156099.ref080], [@pone.0156099.ref081]\].

Practical management options may be more accessible in the short term. Standardised guidelines could recommend continuation of prophylactic therapies such as co-trimoxazole and isoniazid for patients with DIR, or could prompt investigation for subclinical opportunistic infections such as tuberculosis and CMV. Although prevention of DIR through early diagnosis of HIV infection and prompt treatment with ART is likely the most effective intervention \[[@pone.0156099.ref082]--[@pone.0156099.ref085]\], a large proportion of patients worldwide continue to present with advanced HIV infection \[[@pone.0156099.ref086], [@pone.0156099.ref087]\].

This systematic review highlights that a wide range of definitions have been used to characterise clinical outcomes in patients with DIR. These patients are at an increased risk of mortality and are in need of special attention, including integration into HIV clinical trials. We have suggested a definition for DIR based on the limited available data in order to help begin the process of arriving at a consensus definition that could be used to guide clinical care and in future research. We recommend that further studies validate this definition for DIR to aid the development of consensus guidelines.
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